Clinical trials
T Cells clinical trials
Below are recruiting t cells clinical trials, each written for real people, not researchers. We’re tracking 5,686 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05689619Recruiting
Silibinin after one brain metastasis surgery for lung or breast cancer
This trial studies silibinin, a natural substance, to help prevent brain metastasis from coming back after surgery. It is for people with lung (NSCLC) or breast cancer who have exactly one small brain metastasis that is fully removed and has a specific lab marker in the brain tissue.
GenovaAges 18–70 - NCT05692635RecruitingPhase 2
Brain MRI checks to prevent lung cancer brain symptoms
This trial tests whether doing scheduled brain MRI scans can lower the chance that lung cancer later causes symptomatic brain metastases (tumors that cause symptoms in the brain). If you’re eligible, you’ll get brain MRI surveillance at a specific time after starting radiation.
Winston-Salem, North CarolinaAges 18 years+ - NCT05694312RecruitingPhase 2
Ibrutinib for anemia caused by immune destruction in CLL/SLL
This Phase 2 trial tests ibrutinib, a prescription medicine, to treat active autoimmune hemolytic anemia (AIHA) in people with CLL/SLL or a CLL-like condition. It may help reduce anemia when steroids don’t work well, don’t last, or are needed too long.
FlorenceAges 18 years+ - NCT05703126Recruiting
Blood vessel and heart strength tests in AML patients
This study looks at how well your blood vessels and heart pumping ability work in people with acute myeloid leukemia (AML) receiving certain chemotherapy. It may help doctors better understand heart risk during treatment and tailor monitoring to you.
Samara, Samara OblastAges 18–65 - NCT05703516Recruiting
Study of Tabrecta for NSCLC with exon 14 skipping
This study follows people in South Korea who have a specific lung cancer genetic change called “exon 14 skipping” and are going to take Tabrecta (capmatinib). It helps collect real-world safety and results for using this medicine under routine care.
Daegu, Dalseo guAges 18–100 - NCT05713006RecruitingPhase 1/Phase 2
Alectinib drug handling study for ALK-positive advanced lung cancer
This early-phase trial studies how alectinib (an ALK-blocking medicine) moves through the body and how it’s tolerated in people with advanced non-small cell lung cancer (NSCLC) that has an ALK rearrangement. You may be considered if you have ALK-positive, recurrent or advanced disease and have already had specific prior treatments.
Mexico City, Mexico CityAges 18 years+ - NCT05713214Recruiting
Long-term follow-up after a gene-modified cell treatment
This study checks long-term health after receiving a gene-modified cell therapy through a St. Jude study. It helps doctors understand the treatment’s lasting effects and safety over time.
Memphis, TennesseeAges Any age - NCT05715229RecruitingPhase 2
Blood test–guided treatment choice for advanced lung cancer
This Phase 2 study tests how results from blood cancer DNA tests (ctDNA) can help choose the best immune therapy approach for newly diagnosed, advanced lung cancer. It aims to improve outcomes by matching treatment decisions to a patient’s immune and blood test “profile.”
Washington D.C., District of ColumbiaAges 18 years+ - NCT05719779Recruiting
Oral device trial for snoring and sleep apnea in throat cancer
This trial tests whether a custom mouth (mandibular advanced) device can reduce snoring and breathing pauses during sleep in people with oropharyngeal (throat) cancer. It also looks at how well you tolerate the device and whether it helps with sleep symptoms.
Montreal, QuebecAges 18–65 - NCT05722418RecruitingPhase 1
CRISPR-edited CAR-T for harder-to-treat myeloma
This Phase 1 study tests a lab-made immune cell therapy (CAR-T) made from a donor, with a CRISPR edit, for multiple myeloma that has come back or not responded to treatment. It aims to find the safest way to give the treatment and see how well it can control the cancer.
Birmingham, AlabamaAges 18 years+ - NCT05724121Recruiting
Study heart rhythm changes during BTK or venetoclax treatment
This observational study tracks how your heart rhythm (heartbeat pattern) changes while you take a BTK inhibitor or venetoclax. It may help doctors better understand heart rhythm risks in people receiving these cancer-related medicines.
Bethesda, MarylandAges 18–110 - NCT05724004Recruiting
Alectinib then targeted radiation for ALK-positive lung cancer
This trial tests giving alectinib first, then adding targeted radiation to remaining spots of cancer in people with ALK-rearranged advanced non-small cell lung cancer. It aims to control the cancer after an initial response and help keep disease from progressing.
StockholmAges 20 years+ - NCT05728658RecruitingPhase 1
Study of ICP-248 for relapsed or refractory B-cell cancers
This early-phase (Phase 1) study tests ICP-248 in people with certain B-cell cancers that have come back (relapsed) or did not respond to prior treatment (refractory). The goal is to learn the safest dose and whether it can help shrink or control the cancer.
Bengbu, AnhuiAges 18–80 - NCT05736029Recruiting
Using blood and tumor data to predict cancer treatment response
This study looks at “multiomics” information (many types of biological data, like blood and lab markers) to predict how well cancer treatments may work for you. It may help doctors choose better treatments in the future based on what your body is doing during therapy.
Dallas, TexasAges 18 years+ - NCT05748093RecruitingPhase 4
Boost osimertinib levels using cobicistat to improve value
This study tests whether adding cobicistat can increase and stabilize the effect level of osimertinib while keeping treatment cost-effective. You would take osimertinib 80 mg daily, with blood tests to see how your body processes the drug.
Maastricht, LimburgAges 18 years+ - NCT05748197RecruitingPhase 1
Study of ADCLEC.syn1 for relapsed or resistant AML
This Phase 1 study tests ADCLEC.syn1, a new treatment made from a patient’s immune cells, in adults with relapsed or refractory acute myeloid leukemia (AML). The goal is to see how safe it is and how well it may work, especially after standard treatments have not helped.
Basking Ridge, New JerseyAges 18 years+ - NCT05751447Recruiting
Studying immune cells in suspected sarcoidosis
This study looks at immune cells in the lungs, lymph nodes, and blood to learn more about suspected sarcoidosis. You may benefit by helping researchers better understand the condition and by getting close medical evaluation as part of the study.
StockholmAges 18–90 - NCT05751798RecruitingPhase 1/Phase 2
Test drug OSE-279 for advanced lung cancer that has no key mutations
This Phase 1/2 study tests how well and how safely OSE-279 works in people with advanced non-small cell lung cancer (NSCLC) who cannot be cured with surgery or radiation. It also looks at the right dose and how it may help, especially if the tumor has high PD-L1.
AnderlechtAges 18 years+ - NCT05753722RecruitingPhase 1
First trial for PRTH-101 alone or with pembrolizumab
This early study tests PRTH-101, given by itself or with pembrolizumab, in people with advanced cancers that have spread or cannot be removed by surgery. The goal is to see if it is safe and how it affects the cancer.
Scottsdale, ArizonaAges 18 years+ - NCT05756569RecruitingPhase 2
Enfortumab plus pembrolizumab for advanced bladder cancer variants
This trial studies enfortumab vedotin plus pembrolizumab (immunotherapy) for people with advanced bladder cancer that has a “variant” or non-urothelial subtype. It aims to shrink tumors and improve outcomes when standard options have not worked or are no longer enough.
Atlanta, GeorgiaAges 18 years+ - NCT05760391Recruiting
Check anti-PD-1 therapy plus radiation for advanced esophageal cancer
This trial studies whether adding an anti-PD-1 immunotherapy (with chemotherapy) together with radiation can help people with advanced esophageal squamous cell cancer. It’s for cases where surgery or standard definitive chemoradiation can’t be done, or the cancer has spread to distant sites.
ShanghaiAges 18–80 - NCT05765084RecruitingPhase 1/Phase 2
Atezolizumab plus WT1 vaccine with chemo for pleural mesothelioma
This trial studies a treatment plan that combines an immune drug (atezolizumab) and a personalized cancer vaccine (WT1/DC) with standard first-line chemotherapy for epithelioid malignant pleural mesothelioma that cannot be removed with surgery. It aims to improve control of the cancer by helping the immune system work alongside chemotherapy.
Edegem, AntwerpAges 18 years+ - NCT05768035RecruitingPhase 1/Phase 2
Testing SMART101 after half-matched stem cell transplant
This trial studies a new immune treatment called SMART101 given after a half-matched (haploidentical) stem cell transplant that uses post-transplant cyclophosphamide to prevent complications. It mainly checks safety, and may also look at how well SMART101 helps people with blood cancers recover after transplant.
MarseilleAges 18 years+ - NCT05768178RecruitingPhase 2/Phase 3
Vemurafenib plus cobimetinib for BRAF-mutant cancers
This trial tests whether combining two targeted cancer medicines—vemurafenib and cobimetinib—can treat adults whose tumors have a specific “BRAF V600” mutation. You may be screened with blood tests and a tissue biopsy before starting treatment.
BelfastAges 18 years+
Hear when a new T Cells trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for t cells?
- Yes. Clin2 currently lists 5,686 recruiting t cells studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a t cells trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a t cells trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.